Literature DB >> 26321665

Novel splice variants of CXCR4 identified by transcriptome sequencing.

L G L Sand1, A G Jochemsen2, E Beletkaia3, T Schmidt3, P C W Hogendoorn1, K Szuhai4.   

Abstract

Chemokine receptor CXCR4 is involved in tumor growth, angiogenesis and metastasis. Its function is regulated in many ways and one of them is alternative splicing. We identified two novel coding splice variants (CXCR4-3 and CXCR4-4) of CXCR4 in Ewing sarcoma (EWS) cell lines by whole transcriptome sequencing and validated these with reverse transcriptase- PCR and Sanger sequencing. The novel splice variants were expressed at RNA level in Ewing sarcoma samples and in other tumor cell lines and placenta, but not in lung. Due to inclusion of an additional exon the new isoforms have a 70 and 33 amino acid elongation of the N-terminal end of CXCR4. For validation at protein and functional level, the identified isoforms and normal CXCR4 were cloned into an EYFP tagged vector and ectopically expressed in HEK293T cell line and EWS cell line A673. Of the novel isoforms CXCR4-3 showed cell membrane localization and a functional response after addition of CXCR4 ligand CXCL12a. CXCR4-4 showed strong cytoplasmic accumulation and no response to ligand treatment. The role of the newly discovered isoforms in CXCR4 signaling is likely to be limited. Our data stresses the importance of functional validation of newly identified isoforms.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone tumors; CXCR4; Ewing sarcoma; Next generation sequencing; Soft tissue tumor; Splicing

Mesh:

Substances:

Year:  2015        PMID: 26321665     DOI: 10.1016/j.bbrc.2015.08.113

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.

Authors:  Friederike Knipping; Gregory A Newby; Cindy R Eide; Amber N McElroy; Sarah C Nielsen; Kyle Smith; Yongxing Fang; Tatjana I Cornu; Caroline Costa; Alejandra Gutierrez-Guerrero; Samuel P Bingea; Colby J Feser; Benjamin Steinbeck; Keli L Hippen; Bruce R Blazar; Anton McCaffrey; Claudio Mussolino; Els Verhoeyen; Jakub Tolar; David R Liu; Mark J Osborn
Journal:  Mol Ther       Date:  2021-11-02       Impact factor: 12.910

2.  Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.

Authors:  Laurens G L Sand; Tessa Buckle; Fijs W B van Leeuwen; Willem E Corver; Alwine B Kruisselbrink; Aart G Jochemsen; Pancras C W Hogendoorn; Károly Szuhai
Journal:  BMC Cancer       Date:  2017-05-26       Impact factor: 4.430

3.  Splice variants denote differences between a cancer stem cell side population of EWSR1‑ERG‑based Ewing sarcoma cells, its main population and EWSR1‑FLI‑based cells.

Authors:  Eberhard Korsching; Julian Matschke; Marc Hotfilder
Journal:  Int J Mol Med       Date:  2022-01-28       Impact factor: 4.101

4.  The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.

Authors:  Philipp Berning; Christiane Schaefer; Dagmar Clemens; Eberhard Korsching; Uta Dirksen; Jenny Potratz
Journal:  Cell Commun Signal       Date:  2018-05-18       Impact factor: 5.712

5.  Development of a Novel SPR Assay to Study CXCR4-Ligand Interactions.

Authors:  Arnaud Boonen; Abhimanyu K Singh; Anneleen Van Hout; Kalyan Das; Tom Van Loy; Sam Noppen; Dominique Schols
Journal:  Biosensors (Basel)       Date:  2020-10-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.